GET DAILY SIGNALSLiquidia (LQDA): Analyst Consensus Points to $58 Target With +12.8% Upside
Key Takeaways
- The central $58 stock price target is the arithmetic mean of eight verified analyst price targets for Liquidia Corporation (LQDA), rounded from a calculated mean of $58.38.
- The analyst price target range is wide, from a low of $33 (Wells Fargo) to a high of $87 (BTIG), reflecting genuine disagreement about the stock's post-settlement value.
- At a latest verified price near $51.40, reaching $58 implies roughly a 12.8% gain, a modest move by historical standards for this volatile biopharmaceutical name.
- The strongest support is YUTREPIA's rapid commercial ramp and the removal of the United Therapeutics litigation overhang via a global settlement.
- The biggest risks are a narrowed label now limited to PAH (pulmonary arterial hypertension), a $380.7 million cash settlement obligation, and heavy dependence on a single product.
- You can explore more about this ticker's Major News, Today's Price Move, Forecast, and Earnings on additional pages.
- For a broader view of AI-driven market tools, explore Trending AI Robots.
Analyst Consensus on LQDA
The $58 central target is the arithmetic mean of eight current analyst price targets I collected and verified, spanning $33 to $87. The average reflects a split between bullish and more cautious views: six analysts rate the stock Buy, while two (Wells Fargo at $33 and Bank of America at $42) hold Neutral or Equal Weight ratings, with zero Sell ratings. The most recent revisions followed third-quarter results reported on November 10, 2026, when BTIG's Julian Harrison raised his target to $87 from $70, Needham's Serge Belanger raised to $66 from $58, and Jefferies' Amy Li raised to $62 from $55. Other targets include H.C. Wainwright's Andrew Fein at $65, LifeSci Capital's Gaurav Maini at $59, and Raymond James' Ryan Deschner at $53. The wide gap between the $33 low and $87 high underscores how much depends on whether YUTREPIA sustains its growth within a narrower, PAH-only label. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Where LQDA Stands Today
Liquidia Corporation (LQDA) closed near $51.40, so reaching $58 requires a rise of about 12.8%, a modest move. The stock sits roughly in the middle of a 52-week range of $22.31 to $93.61, having rebounded sharply from an early-October low after a global settlement with United Therapeutics resolved six lawsuits. The path toward the target hinges on YUTREPIA, the company's inhaled treprostinil therapy for PAH. Third-quarter net product sales rose 31% sequentially to $222.7 million, and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $140.5 million, a fifth straight quarterly increase. Management has not yet issued 2027 guidance, saying it will update investors in early January, leaving the near-term narrative driven by prescription and referral trends rather than formal forecasts.
Bullish Factors for LQDA
The strongest tailwind is commercial execution. YUTREPIA delivered five consecutive quarters of growth, with a gross margin near 94% and meaningful operating leverage as SG&A (selling, general, and administrative) expense fell to 26% of revenue from 33%. Prescriber breadth is expanding, with about 1,300 prescribers, more first-time prescribers in October than September, and conversion of referrals above 87%. Management estimates a U.S. PAH prostacyclin market of roughly $4 billion, arguing penetration remains small. The litigation resolution also removes a key overhang, and the company has said it can fund the $380.7 million settlement from cash and ongoing sales without raising capital. The L606 program and studies in SSc-RP (systemic sclerosis-associated Raynaud's phenomenon) provide additional, longer-term optionality.
Key Risks to Consider
The principal obstacles are structural. The settlement narrows YUTREPIA's approved label to PAH, requiring removal of the PH-ILD (pulmonary hypertension associated with interstitial lung disease) indication, which caps the addressable market versus earlier assumptions and prompted several analysts to slash targets dramatically in October. The company owes roughly $380.7 million in cash through April 2027, and it remains highly concentrated in a single product. Competition from United Therapeutics' Tyvaso franchise and potential future entrants, plus the risk that referral growth decelerates once post-settlement clarity normalizes, could pressure sentiment. Because the stock already reflects substantial expectations, any disappointment in fourth-quarter results or 2027 guidance could trigger valuation compression.
Technical Picture for the Stock
Liquidia Corporation (LQDA)'s stock has been exceptionally volatile: it traded near $83 in August 2026, fell to a 52-week low of $22.31 on October 1 after an adverse court ruling, then rebounded roughly 115% following the settlement. The $22–$23 zone now marks a durable support area from that capitulation low, while the $93.61 52-week high and the mid-$80s prior plateau represent major resistance overhead. The stock remains below its 200-day moving average, reported near $54.38, a level it would need to reclaim to confirm a longer-term trend change. From what I see, these levels help frame the risk-reward around the consensus target.
What to Watch Going Forward
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms may differ and none specifies a precise date. The most important near-term catalysts are fourth-quarter results and 2027 guidance expected in early January 2027, along with any further analyst revisions as they reassess the PAH-only revenue base. Investors should also track monthly prescription and referral data, the FDA's review of the Prior Approval Supplement removing the PH-ILD label language, enrollment progress in the Re-Spire and AMPLIFY-PAH studies, and any new patent assertions by United Therapeutics against the pipeline. I'm watching this closely as the data rolls in.
Final Assessment
Can Liquidia Corporation (LQDA) stock reach $58? The target is a modest 12.8% above the latest price and represents the average of eight analyst targets, so it is far from a stretch by the stock's own volatile history. The case rests on YUTREPIA's demonstrated commercial momentum, improving operating leverage, and the removal of a major legal overhang. The counterargument rests on the narrowed PAH-only label, the cash settlement burden, and a valuation that already prices in continued strong growth. With a range spanning $33 to $87, the Street itself is divided on how much of the pre-settlement opportunity remains. The upcoming fourth-quarter report and 2027 outlook will likely determine whether the stock can close that 12.8% gap.
AI Daily Buy/Sell Signals
In my research process, I frequently review Tickeron’s AI Daily Buy/Sell Signals to monitor how technical conditions align with the fundamental story on names like this. The tool applies artificial intelligence across thousands of stocks to flag Buy, Sell, or Hold signals based on shifting market dynamics. Pairing it with independent analysis has helped me add a technical layer without replacing core due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
LQDA's RSI Oscillator climbs out of oversold territory
The RSI Indicator for LQDA moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 22 of the 24 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LQDA as a result. In 70 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for LQDA just turned positive on October 16, 2026. Looking at past instances where LQDA's MACD turned positive, the stock continued to rise in 46 of 53 cases over the following month. The odds of a continued upward trend are 87%.
LQDA moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +15.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where LQDA advanced for three days, in 280 of 325 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 200 of 247 cases where LQDA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 55 of 68 cases where LQDA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.
The 50-day moving average for LQDA moved below the 200-day moving average on October 28, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LQDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
LQDA broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. LQDA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.369) is normal, around the industry mean (6.379). P/E Ratio (28.101) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (14.286) is also within normal values, averaging (183.387).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of particle-based vaccines and therapeutics for prevention and treatment of human disease
Industry PharmaceuticalsGeneric
Advertisement